Currency converter
^
News Feed
News Search Topics
ОК
Use filter
You can filter your feed,
by choosing only interesting
sections.
Loading

Phase 2a Clinical Study Data of AJM300 Will Be Presented in Digestive Disease Week 2014

April 16, 2014, 9:00 UTC+3
The contents of data will be presented at the beginning of Joint Presidential Plenary Session by the American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association
1 pages in this article
© ajinomoto.com

TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association.

- Study data to be presented (Presentation date / time: USA Eastern time zone)

Abstract No.: 370

Title: AJM300, an Oral alpha 4 Integrin Antagonist, for Active Ulcerative Colitis: a Multicenter, Randomized, Double-Blind, Placebo- Controlled* Phase 2A Study

Presentation date / time: May 4, 2014, 1:36-1:46 PM, Oral presentation

*Randomized double-blind, placebo-controlled study

Randomized double-blind, placebo-controlled study is a method of study to objectively evaluate the efficacy of medicine. In the study, neither investigators nor patients know which the patient takes a placebo (a mimic preparation that looks like a study drug but contains no active ingredient) or the study drug.

About Ajinomoto Pharmaceuticals Co., Ltd.
Representative Director,President & CEO: Takashi Nagamachi
Headquarters, Chuo-ku, Tokyo

 

Contact:

Hajime Ito, Corporate Planning Dept, Ajinomoto Pharmaceuticals Co., Ltd.

Tel: +81-3-6280-9802

contact_ajis@ajinomoto.com

Show more
In other media
Реклама
Реклама